Endocrinology, Vol 127, 185-190, Copyright © 1990 by Endocrine Society

ARTICLES

Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3E1) cells

M Noda, RL Vogel, DM Hasson and GA Rodan
Department of Bone Biology and Osteoporosis Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.

The effect of leukemia inhibitory factor (LIF) on proliferation and phenotypic expression in murine osteoblast-like (MC3T3E1) cells was examined. LIF inhibited the proliferation of these cells by up to 20% and DNA synthesis was inhibited in a dose-dependent manner with an ED50 of about 0.2 ng/ml. The effect of LIF relative to matched controls increased with decreasing serum concentration, reaching 30% inhibition at 0.2% serum. LIF also reduced the stimulatory effects of platelet- derived growth factor and insulin-like growth factor I on DNA synthesis. The inhibition of the DNA synthesis by saturating concentration of transforming growth factor beta was further enhanced by the addition of LIF, suggesting independent pathways for the action of the two growth inhibitors. In addition, LIF reduced alkaline phosphatase activity and the abundance of type I collagen messenger RNA, but increased the level of osteopontin messenger RNA. These findings suggest that LIF may play a role in regulating the function of osteoblasts.

This article has been cited by other articles:

				D. Falconi, K. Oizumi, and J. E. Aubin Leukemia Inhibitory Factor Influences the Fate Choice of Mesenchymal Progenitor Cells Stem Cells, February 1, 2007; 25(2): 305 - 312. [Abstract] [Full Text] [PDF]

				Y. Ohyama, A. Nifuji, Y. Maeda, T. Amagasa, and M. Noda Spaciotemporal Association and Bone Morphogenetic Protein Regulation of Sclerostin and Osterix Expression during Embryonic Osteogenesis Endocrinology, October 1, 2004; 145(10): 4685 - 4692. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]

				K. K. Frick and D. A. Bushinsky In vitro metabolic and respiratory acidosis selectively inhibit osteoblastic matrix gene expression Am J Physiol Renal Physiol, November 1, 1999; 277(5): F750 - F755. [Abstract] [Full Text] [PDF]

				K. K. Frick and D. A. Bushinsky Chronic metabolic acidosis reversibly inhibits extracellular matrix gene expression in mouse osteoblasts Am J Physiol Renal Physiol, November 1, 1998; 275(5): F840 - F847. [Abstract] [Full Text] [PDF]

				Y. Tintut, F. Parhami, K. Bostrom, S. M. Jackson, and L. L. Demer cAMP Stimulates Osteoblast-like Differentiation of Calcifying Vascular Cells. POTENTIAL SIGNALING PATHWAY FOR VASCULAR CALCIFICATION J. Biol. Chem., March 27, 1998; 273(13): 7547 - 7553. [Abstract] [Full Text] [PDF]

				T. Bellido, V. Z. C. Borba, P. Roberson, and S. C. Manolagas Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal Transduction Pathway by Interleukin-6-Type Cytokines Promotes Osteoblast Differentiation Endocrinology, September 1, 1997; 138(9): 3666 - 3676. [Abstract] [Full Text] [PDF]

				F. Parhami, A. D. Morrow, J. Balucan, N. Leitinger, A. D. Watson, Y. Tintut, J. A. Berliner, and L. L. Demer Lipid Oxidation Products Have Opposite Effects on Calcifying Vascular Cell and Bone Cell Differentiation : A Possible Explanation for the Paradox of Arterial Calcification in Osteoporotic Patients Arterioscler. Thromb. Vasc. Biol., April 1, 1997; 17(4): 680 - 687. [Abstract] [Full Text]